Most colorectal patients report financial burden due to treatment
the ONA take:
The burden of cancer and its treatment goes beyond the obvious medical and physical challenges. Many patients experience significant financial hardship as well. Researchers at the University of Michigan Comprehensive Cancer Center conducted a study on the financial burden of colorectal cancer.
They surveyed 956 patients identified through the Surveillance, Epidemiology and End Results cancer registries for the Metro Detroit area and the stage of Georgia. The patients were asked to complete a seven-question survey that asked whether they employed such financial strategies as using savings, borrowing money, skipping bill payments, or cutting back on expenses (eg, food, clothing, or recreational activities).
Overall, 62% of respondents indicated areas of burdens, based on the seven questions. More specifically, the study demonstrated that younger patients who worked in low-paying jobs and those who received chemotherapy were most likely to endure financial burdens.
Based on their findings, the researchers advocate changes to job-related policies that would allow patients to focus on adhering to their treatments, and provide support for both copays and nonmedical expenses related to getting to treatment appointments. Most importantly, however, the researchers encourage clinicians to openly discuss financial situations and support options with patients.
Researchers conducted a study on the financial burden of colorectal cancer.
Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The burden was greatest among patients who received chemotherapy and among younger patients who worked in low-paying jobs.
The study surveyed 956 patients who had been treated for stage 3 colorectal cancer. Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following surgery.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|